Acute Respiratory Distress Syndrome Therapeutics Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports

Pune, Jan. 18, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global acute respiratory distress syndrome therapeutics market is expected to clock US$ 2.63 billion by 2030 and to grow at a CAGR of 7.3% during the forecast period. Owing to the increasing cases of acute respiratory distress syndrome cases globally. This exclusive information is published by Growth Plus Reports in its report titled “Acute Respiratory Distress Syndrome Therapeutics Market – Global Outlook & Forecast 2022-2030”

Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/acute-respiratory-distress-syndrome-therapeutics-market/8032

Growth Drivers

The ARDS market is expanding as a result of numerous causes. Rising ARDS prevalence, increased R&D activity, the opportunistic market for novel medications, and other variables are among the important ones. Additionally, the anticipated approval of novel medicines and the rising number of patients with acute respiratory distress syndrome both directly contribute to the larger ARDS market size.

The global acute respiratory distress syndrome therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global acute respiratory distress syndrome therapeutics market is segmented into:

• Corticosteroids
• Antimicrobials
• Bronchodilators
• Other Medications

The most popular product on the market was corticosteroids. The only medications that have shown promise as a potential treatment for ARDS are corticosteroids, which have undergone the most comprehensive testing. Since they contain anti-inflammatory and anti-fibrotic qualities, they have been researched as a possible ARDS treatment. The second-largest market share holder, a bronchodilator, is anticipated to rise rapidly over the course of the projection period. The pharmacological class known as bronchodilators relaxes and widens the bronchi, or airways, in the lungs. It functions by letting the airway muscles relax. In addition to bronchodilators, corticosteroids, and antibiotics, ARDS has also been treated with lung surfactants, diuretics, NSAIDs, anticoagulants, etc.

Excerpts from ‘By Region Segmentation’

Based on region, the global acute respiratory distress syndrome therapeutics market has been segmented into:

• North America
• Europe
• Asia Pacific
• Rest of the World

Asia Pacific is the fastest-growing region in the market owing to factors such as the region's increasing air pollution levels, lifestyle-related illnesses, rise in the aging population, and rising healthcare costs. Furthermore, lung injury and brain damage from automobile accidents are also leading the way in driving the growth of the market in the region. Due to the low cost of raw materials and the availability of a large patient pool, many major industry competitors are attempting to enter the Asia Pacific market.

Browse Full Report with detailed TOC at: https://www.growthplusreports.com/report/acute-respiratory-distress-syndrome-therapeutics-market/8032

Excerpts from ‘Competitive Landscape’

The prominent players operating in the global acute respiratory distress syndrome therapeutics market are

• Akebia Therapeutics, Inc.
• Genentech Inc.
• Boehringer Ingelheim International GmbH
• Chiesi Farmaceutici S.p.A.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Pfizer Inc.
• Direct Biologics LLC
• HEALIOS K.K.
• Edesa Biotech, Inc.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecasted Years – 2022 to 2030
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2021) 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
   1. Bronchodilators
   2. Corticosteroids
   3. Antimicrobial Agents
   4. Other Drug Class
6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Inquiry Before Buying: https://www.growthplusreports.com/inquiry/before-buying/acute-respiratory-distress-syndrome-therapeutics-market/8032

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.